PD-0212 SURVIVAL AFTER PET/CT PLANNED CONCOMITANT BOOST (IMRT) TO LYMPH NODE METASTASIS IN PATIENTS WITH CERVICAL CANCER

Purpose/Objective: In cancer of the uterine cervix, lymph node metastasis (LN) has been associated with a poor prognosis. The purpose of the current study was to evaluate the effect of the introduction of PET/CT-planned Intensity Modulated Radiotherapy (IMRT) on survival in patients with cervical cancer with LN Materials and Methods: A single institution retrospective analysis of survival and characteristics in cervical cancer patients with LN Inclusion criteria: Histopatological diagnose of cervical cancer, approved curative intended IMRT plan for patients with pelvic and/or para aortic fields, lymph node metastasis verified by CT, PET/CT and/or lymph node biopsy. Cisplatin based chemotherapy concomitant to IMRT. Consecutive patients from 1. January 2000 to 15. September 2011 with primary pelvicor para aortic LN, or recurrence of para aortic LN after primary treatment were included. IMRT was given as a sliding window technique and PET/CT planed on an Eclipse (Varian) doseplanning system. Doses to CTV: 50 Gy and a concomitant boost to LN: 60-64 Gy. Furthermore, patients with primary tumors received PDR brachytherapy 17.5 Gy x 2 Survival statistics and Kaplan Meier plots were calculated using SPSS. The distribution of patient characteristics was also tested. Results: Eighty-three patients were included. Patient characteristics are listed in Table 1. The statistical analysis indicated significant differences in the distributions of histopathology between the three groups. For both age and stage, no significant differences was found.